AstraZeneca PLC ADR (AZNN)

1,256.61
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    1,199.00/1,297.00
  • Day's Range:
    1,256.61 - 1,280.00

AZNN Overview

Prev. Close
1,276
Day's Range
1,256.61-1,280
Revenue
894.65B
Open
1,280
52 wk Range
1,061.01-1,430
EPS
1.32
Volume
0
Market Cap
3.97T
Dividend (Yield)
1.42
(2.19%)
Average Volume (3m)
2,691
P/E Ratio
99.63
Beta
0.168
1-Year Change
1.83%
Shares Outstanding
1,549,516,692
Next Earnings Date
-
What is your sentiment on AstraZeneca ADR?
or
Market is currently closed. Voting is open during market hours.

AstraZeneca PLC ADR News

AstraZeneca PLC ADR Analysis

AstraZeneca PLC ADR Company Profile

AstraZeneca PLC ADR Company Profile

Employees
83100
  • Type:Equity
  • Market:Mexico
  • ISIN:US0463531089
  • S/N:046353108

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company’s marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Read More

Analyst Price Target

Average71.90 (+8.66% Upside)
High80
Low54.5
Price66.17
No. of Analysts5
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellNeutralStrong BuyStrong Buy
Technical IndicatorsNeutralSellSellStrong BuyBuy
SummarySellStrong SellNeutralStrong BuyStrong Buy
  • do not buy this stock, it's a trap
    1
    • Junk like pfizer
      1
      • why is this stock so stagnant? even with good news it seems to drop.
        0
        • Japan, AstraZeneca agree on 120 mil. COVID-19 vaccine dose supply KYODO NEWS - 2 hours ago - 21:49 | All, Japan, Coronavirus
          1
          • I dont get how this company pumps out good news and a potential merger and the stock moves by pennies. what will it take for this stock to jump?
            0
        • Get into it before FDA approves vaccine
          2
          • is it too late to get in?
            2
            • Not really man,Its just the beginning.Its gonna be late 3 weeks after.
              0
            • I think it's a good time. this stock is stable historically and pays dividends. I bought at 62 so I'm down big but have faith it will be good long term.
              0
            • 0